Prescription Medicines
Bepzole Tab. 20mg
- Product Category
- Peptic ulcer treatment
- Active Ingredients
- Rabeprazole sodium
- Appearance
- Light yellow round enteric film-coated tablet
- Reimbursement Code
- 648103440
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Rabeprazole sodium (JP, Byeolgyu) ----- 20mg
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow / pork, pork)
- Other additives: magnesium oxide, iron oxide, titanium oxide, sodium hydroxide, low-substituted hydroxypropyl cellulose, talc, polyethylene glycol 6000, hydroxypropyl cellulose, hypromellose phthalate, hypromellose 2910, D-mannitol.
2. Effectiveness
- Gastric ulcer, duodenal ulcer
- Erosive or ulcerative gastroesophageal reflux disease
- Relieve symptoms of gastroesophageal reflux disease
- Long-term maintenance treatment for gastroesophageal reflux disease
- Antibiotic combination therapy for patients with digestive ulcers infected with Helicobacter pylori
- Zollinger-Ellison syndrome
3. Dosage and dosage
- Gastric ulcer, duodenal ulcer: Usually, 10 mg of rabeprazole sodium is administered orally once a day to adults. Depending on symptoms, 20 mg can be administered orally once a day. Typically, it is administered for up to 8 weeks for gastric ulcers and up to 6 weeks for duodenal ulcers.
- Erosive or ulcerative gastroesophageal reflux disease: Administer 10 mg or 20 mg once a day for 4 to 8 weeks. If treatment is not achieved after 8 weeks of proton pump inhibitor (PPI) administration, 10 mg or 20 mg can be administered orally twice a day for an additional 8 weeks. However, administration of 20 mg twice daily is limited to patients with confirmed severe mucosal damage.
- Relief of symptoms of gastroesophageal reflux disease: Administer 10 mg once a day. If symptoms are not controlled even after 4 weeks of treatment, additional treatment is required. After symptoms disappear, subsequent symptoms can be controlled using on-demand therapy, administering 10 mg once a day when necessary.
- Long-term maintenance treatment for gastroesophageal reflux disease: 10 mg or 20 mg orally per day depending on the patient.
- Helicobacter pylori eradication: Patients with Helicobacter pylori infection should be treated with eradication therapy. It is recommended to administer 20 mg of this drug, 500 mg of clarithromycin, and 1 g of amoxicillin twice a day for 7 days.
- Zollinger-Ellison syndrome: The recommended initial dose for adults is 60 mg once a day. The dosage can be adjusted up to 120 mg per day depending on the needs of each patient. Up to a 100 mg dose can be administered once a day, and a 120 mg dose is administered in divided doses of 60 mg twice a day. Patients with Zollinger-Ellison syndrome have had experience taking this drug for up to one year.
- Patients with liver impairment: Adverse reactions of hepatic encephalopathy have been reported in patients with liver cirrhosis. Therefore, it must be administered with caution.
- Children: Safety in children has not been established.
- Elderly: Administer with caution as liver function is often reduced.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug, its components, or benzimidazoles
2) Patients with hypersensitivity to penicillin antibiotics (when combined with amoxicillin to eradicate Helicobacter pylori)
3) Patients with hypersensitivity to macrolide antibiotics (limited to combined use with clarithromycin to eradicate Helicobacter pylori)
4) Patients receiving terfenadine, cisapride, pimozide, and astemizole (limited to combined use with clarithromycin to eradicate Helicobacter pylori) (see interaction section)
5) Patients receiving atazanavir
6) Pregnant and lactating women
7) Patients taking rilpivirine (see interaction section)
2. Administer with caution to the following patients:
1) Patients with liver impairment
2) Elderly people (refer to the section on administration to elderly people)
3) Patients with a history of drug hypersensitivity reaction
3. Adverse reactions
1) Hypersensitivity reaction: Occasionally rash, hives, and itching may occur. If these symptoms appear, discontinue administration.
2) Blood system: Decreased red blood cells, decreased leukocytes, increased leukocytes, increased eosinophilia, increased neutrophils, decreased lymphocytes, anemia, ecchymosis, lymphadenopathy, hypochromic anemia, decreased pancytemia, agranulocytosis, decreased thrombocytopenia, hemolytic anemia, etc. may occur, so it is advisable to perform regular hematological tests during administration. Additionally, if abnormalities appear, take appropriate measures, such as discontinuing administration.
3) Liver: Occasionally, elevations of ALT, AST, ALP, γ-GTP, LDH, and total bilirubin may occur, so it is advisable to conduct blood biochemical tests regularly during administration. Fulminant hepatitis, liver dysfunction, and jaundice may occur. If abnormalities appear, take appropriate measures, such as discontinuing administration.
4) Cardiovascular system: Hypertension, myocardial infarction, electrocardiogram abnormalities, migraine, syncope, angina pectoris, bundle branch block, palpitations, sinus bradycardia, tachycardia, rarely bradycardia, pulmonary embolism, supraventricular tachycardia, thrombophlebitis, vasodilatation, QTC prolongation, and ventricular tachycardia may occur.
5) Digestive system: Diarrhea, occasional constipation, abdominal pain, abdominal distension, indigestion, belching, nausea, rectal bleeding, bloody stool, anorexia, cholelithiasis, oral ulcer, dysphagia, gingivitis, cholanitis, hyperappetite, abnormal stool, colitis, esophagitis, glossitis, pancreatitis, proctitis, rarely dry mouth, vomiting, lower abdominal pain, gastric body, gastritis, stomatitis, dysgeusia, hemorrhagic diarrhea, Cholangitis, duodenitis, gastrointestinal bleeding, hepatic encephalopathy, hepatitis, liver cancer, liver fat accumulation, salivary gland enlargement, and thirst may occur.
6) Mental nervous system: Headache, insomnia, anxiety, dizziness, convulsions, abnormal dreams, decreased libido, neuropathy, paresthesia, tremors, sometimes asthenia, nervousness, drowsiness, and in rare cases, vertigo and depression may occur. In rare cases, agitation, amnesia, confusion, extrapyramidal syndrome, and excessive circulating blood flow may occur. In addition, in one case of a cirrhotic patient, there were reports of upper and lower extremity weakness, dullness of perception, decreased grip strength, speech confusion, and staggering, and in one case of a cirrhotic patient with a previous history of hepatic coma in a foreign country, there were reports of confusion, disorientation, and lethargy.
7) Respiratory system: Cough, pharyngitis, rhinitis, difficulty breathing, asthma, nosebleeds, laryngitis, hiccups, hyperventilation, and sometimes bronchitis and sinusitis may occur. In rare cases, apnea and respiratory depression may occur. Since interstitial pneumonia may occur, if fever, cough, difficulty breathing, abnormal lung sounds, etc. are confirmed, administration of this drug should be discontinued, a chest X-ray should be promptly performed, and appropriate measures should be taken.
8) Musculoskeletal system: Muscle pain, back pain, arthritis, leg cramps, bone pain, arthrosis, bursitis, hypertonia, neuralgia, and in rare cases, single contraction may occur.
9) Skin and appendages: Rash, itching, sweating, urticaria, alopecia, rarely dry skin, shingles, psoriasis, skin color change, toxic epidermal necrolysis (Riel syndrome), mucocutaneous ocular syndrome (Stevens-Johnson syndrome), and erythema multiforme may occur.
10) Special senses: Cataracts, amblyopia, glaucoma, dry eyes, abnormal vision, tinnitus, otitis media, rarely corneal opacity, blurred vision, double vision, hearing loss, eye pain, retinal degeneration, and strabismus may occur.
11) Urinary system: Proteinuria, cystitis, frequent urination, dysmenorrhea, dysuria, renal stones, uterine bleeding, polyuria, rarely breast enlargement, hematuria, erectile dysfunction, vaginal discharge, menorrhagia, orchitis, urinary incontinence, interstitial renal tubulitis (possibility of progressing to renal failure) may occur.
12) Others: Occasionally, edema, elevation of total cholesterol, neutral fat, BUN, thyroid stimulating hormone in the blood, chest pain, chills, fever, urinary tract infection, erythema, and in rare cases, malaise, weight gain, visual abnormalities, loss of appetite, neck stiffness, photosensitivity reaction, hangover effect, weight loss, and gout may occur. There are reports that other proton pump inhibitor drugs (omeprazole, lansoprazole) rarely cause anaphylactic reactions and shock, so if abnormalities appear, stop administration and take appropriate measures.
13) Adverse reactions reported in foreign countries after marketing
Elevated liver enzyme levels have been reported, and in rare cases, hepatitis and jaundice have been reported. Hepatic encephalopathy has been rarely reported in patients with cirrhosis. Sudden death, coma, hyperammonemia, rhabdomyolysis, disorientation, delirium, anaphylaxis, and angioedema have been reported. Additionally, in rare cases, hypomagnesemia, thrombocytopenia, neutropenia, leukopenia, agranulocytosis, hemolytic anemia, pancytopenia, bullous or urticarial skin rash, systemic allergic reactions (hypotension, dyspnea, facial edema, etc.), muscle pain, and arthralgia have been reported. Very rarely, interstitial nephritis, gynecomastia, interstitial pneumonia, elevated thyroid-stimulating hormone, erythema multiforme, toxic epidermal necrolysis (Riel syndrome), and mucocutaneous ocular syndrome (Stevens-Johnson syndrome) have been reported. Increases in INR and prothrombin time have been reported when used in combination with warfarin. Bone fractures have been reported. No other significant abnormal results related to rabeprazole treatment were reported in laboratory tests. Clostridium difficile diarrhea may occur (frequency unknown).
The following are adverse reactions reported through post-marketing surveillance of proton pump inhibitors. Because these adverse reactions are voluntarily reported from an unspecified population, it is not always possible to reliably predict their incidence or establish a causal relationship with drug administration.
- Immune system: Systemic lupus erythematosus
- Skin and subcutaneous tissue system: Cutaneous lupus erythematosus
14) Domestic post-marketing survey results
As a result of a use result survey conducted on 53,109 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 0.47% (250 cases/53,109 cases) regardless of causal relationship.
(1) Digestive system: nausea, constipation, abdominal pain, diarrhea, indigestion, abdominal distension, burping, dry mouth, bad breath, glossitis, dry mouth, vomiting, abnormal taste, gastritis, abnormal liver function, increased ALT, increased AST
(2) Systemic and metabolic abnormalities: chest tightness, allergic reaction, fever, edema, hypertriglyceridemia, hypercholesterolemia, weight loss
(3) Nervous system: headache, dizziness, confusion, asthenia, numbness in hands and feet, anxiety, insomnia, drowsiness
(4) Skin and appendages: hives, rash, itching, facial swelling, flushing
(5) Musculoskeletal system: joint pain, muscle pain
(6) Respiratory system: cough, difficulty breathing
(7) Others: palpitations, increased intraocular pressure, visual abnormalities, urinary tract infection
4. General precautions
1) This drug may alleviate the symptoms of malignant tumor or delay the diagnosis, so if there are warning symptoms of suspected malignant tumor (unintentional significant weight loss, recurrent vomiting, difficulty swallowing, hematemesis, melena, etc.) and gastric ulcer is present or suspected, the drug must be administered after confirming that it is not malignant.
2) During treatment, the progress should be observed sufficiently and this drug should be administered at the minimum dose and appropriate treatment period depending on the symptoms. When undergoing long-term treatment with this drug (especially more than 1 year), patients should be examined regularly.
3) No dosage adjustment is necessary for patients with renal impairment. While taking this drug, it is advisable to pay attention to blood status and liver function and perform regular hematological and blood biochemical tests. Additionally, if abnormalities are recognized, appropriate measures, such as discontinuation of administration, are taken.
4) Because there is insufficient long-term use experience for gastric ulcers, duodenal ulcers, and anastomotic ulcers, it is not recommended to use it for maintenance therapy.
5) In an observational study, it was reported that proton pump inhibitor treatment may be associated with an increased risk of fractures associated with osteoporosis of the hip, wrist, and spine. The risk of fracture was increased in patients receiving higher doses than the recommended dose and in patients using the drug for long-term use of more than 1 year.
6) Hypomagnesemia was rarely reported in patients treated with proton pump inhibitors for more than 3 months, and was most common in patients treated for more than 1 year. For most patients, treatment of hypomagnesemia requires magnesium supplementation and discontinuation of proton pump inhibitors. Patients requiring long-term treatment or taking concomitant medications such as digoxin or drugs that cause hypomagnesemia (e.g. diuretics) require periodic monitoring of magnesium levels, including at the start of treatment. Serious adverse reactions include rigidity, arrhythmias, and seizures.
7) When stomach acidity decreases due to proton pump inhibitors, the number of bacteria normally present in the gastrointestinal tract increases. Treatment with this medicine may slightly increase the risk of infections of the gastrointestinal tract caused by bacteria such as Salmonella, Campylobacter, and Clostridium difficile. This is associated with an increased risk of Clostridium difficile diarrhea, and several observational studies have reported that this risk is particularly increased in hospitalized patients. This diagnosis should be considered when diarrhea symptoms do not improve. Clostridium difficile diarrhea has been reported during use of almost all antibacterial agents.
8) Based on the pharmacological properties and adverse reactions that occurred, this drug is not expected to affect driving ability or the ability to operate machinery. However, as drowsiness can reduce your agility, avoid driving or operating complex machinery.
9) Methotrexate: There have been literature reports that when proton pump inhibitors and methotrexate are used together (mainly when using high doses, see precautions for the use of methotrexate), the serum concentration of methotrexate and/or its metabolites increases and persists, leading to methotrexate toxicity. When high doses of methotrexate are used, temporary discontinuation of the proton pump inhibitor may be considered (see Interaction section).
10) As a combination therapy with antibiotics to eradicate Helicobacter pylori, you should refer to the instructions for use of the antibacterial agent administered together with this drug.
11) Long-term administration of this drug may cause vitamin B12 (cyanocobalamin) malabsorption due to hypochlorhydria or anacidosis.
12) Skin and systemic lupus erythematosus: Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking proton pump inhibitors. These cases occurred newly or as a result of worsening of existing autoimmune diseases. Most cases of lupus erythematosus caused by proton pump inhibitors were cutaneous lupus erythematosus.
The most common form of cutaneous lupus erythematosus reported in patients taking proton pump inhibitors is subacute cutaneous lupus erythematosus, which occurs within weeks to years of continuous drug treatment in patients ranging from infants to the elderly. In general, histological results showed no organ invasion.
Systemic lupus erythematosus has been reported less commonly than cutaneous lupus erythematosus in patients taking proton pump inhibitors. Proton pump inhibitor-related systemic lupus erythematosus usually shows milder symptoms than non-drug-induced systemic lupus erythematosus. Systemic lupus erythematosus mainly occurs within a few days to several years after initial drug treatment in young adults to the elderly. The majority of patients presented with a rash, but arthralgia and cytopenias were also reported.
Do not take proton pump inhibitors for longer than medically indicated. If a patient taking this drug develops symptoms or signs consistent with cutaneous lupus erythematosus or systemic lupus erythematosus, stop taking the drug and refer the patient to an appropriate specialist for evaluation. Most patients improved simply by discontinuing proton pump inhibitors within 4 to 12 weeks. Serological tests (e.g., antinuclear antibody (ANA)) may be positive, and high serological test results may take longer to resolve than clinical symptoms.
13) The decrease in gastric acidity caused by the administration of this drug increases the concentration of serum chromogranin A (CgA). Therefore, people taking this drug may experience false positive results in neuroendocrine tumor diagnostic tests. Administration of this drug should be temporarily discontinued at least 14 days before the CgA test. If the test value exceeds the upper reference limit, retesting should be considered. When tests are performed repeatedly (e.g., monitoring), concentration measurements should be performed in the same laboratory because reference ranges differ between laboratories.
14) Acute interstitial renal tubulitis: Acute interstitial renal tubulitis has been observed in patients receiving proton pump inhibitors and can occur at any time during proton pump inhibitor treatment. Patients may exhibit a variety of signs and symptoms, ranging from hypersensitivity reactions to non-specific symptoms of renal dysfunction (e.g., malaise, nausea, loss of appetite). In reported case series, some patients were diagnosed by biopsy and had no extrarenal symptoms (e.g. fever, rash, arthralgia).
Acute interstitial renal tubulitis may progress to renal failure.
Patients suspected of having acute interstitial renal tubulitis should discontinue treatment with this drug and take appropriate measures.
5. Interaction
1) Like other proton pump inhibitor drugs, this drug is metabolized through the CYP-450 system, a hepatic metabolic system. In tests conducted on healthy adults, this drug did not show clinically significant interactions with amoxicillin or drugs metabolized by the CYP-450 system such as warfarin, phenytoin, theophylline, and diazepam. (Omeprazole, another PPI drug, has been reported to delay the metabolism and excretion of phenytoin.)
There have been reports of increased INR and prothrombin time in patients receiving warfarin in combination with proton pump inhibitors, including this drug. Increased INR and prothrombin time can cause abnormal bleeding and even death.
2) In in vitro tests with human liver microsomes, this drug was metabolized by CYP-450 (CYP2C19 and CYP3A4) enzymes. In these tests, blood concentrations of rabeprazole in humans did not inhibit or induce CYP3A4. In an in vitro test with human liver microsomes, this drug inhibited the metabolism of cyclosporine, and the IC50 was 62 μM, which is more than 50 times the highest blood concentration measured in healthy volunteers after taking 20 mg for 14 days. This degree of inhibition is similar to that of omeprazole at the same concentration.
3) Atazanavir - When atazanavir 300 mg/ritonavir 100 mg and omeprazole (40 mg once daily) or atazanavir 400 mg and lansoprazole (60 mg once daily) were coadministered to healthy volunteers, atazanavir exposure was substantially reduced. Atazanavir absorption is pH dependent. Concomitant administration with this drug has not been studied, but similar results are expected as with other proton pump inhibitors. Therefore, proton pump inhibitors, including this drug, should not be administered simultaneously with atazanavir.
4) This drug inhibits gastric acid secretion significantly and continuously for a long period of time. There may be interactions with drugs whose absorption varies depending on the concentration of stomach acid. When administered in combination with this drug, the blood concentration of ketoconazole decreased by approximately 30% and the trough blood concentration of digoxin increased by 22% in normal subjects. Additionally, when this drug is administered together with itraconazole and gefitinib, there is a risk that the blood concentration of these drugs may decrease. Therefore, if dose adjustment is necessary due to co-administration of these drugs and this drug, it should be determined through monitoring for each patient.
5) In clinical trials conducted to check the interaction with antacids when using this drug together with antacids, no interaction was observed with liquid antacids. There have been reports that the average area under the blood concentration curve decreased by 8% and 6%, respectively, when this drug was administered simultaneously with aluminum hydroxide gel and an antacid containing magnesium hydroxide and when taken 1 hour after the administration of the antacid.
6) In a Japanese clinical trial in which a low-fat diet was consumed, there were no clinically relevant interactions with food. When this drug is administered with a high-fat meal, absorption of this drug may be delayed for up to 4 hours or more, but the extent of absorption (AUC) and peak blood concentration remain unchanged.
7) Combination treatment with antibiotics: 20 mg of this drug, 1,000 mg of amoxicillin, and 500 mg of clarithromycin were administered alone or in combination to 16 healthy volunteers, and a cross-over test was conducted. The AUC and peak blood concentrations of clarithromycin and amoxicillin were similar to those of monotherapy. The AUC and peak blood concentration of rabeprazole increased by 11% and 34%, respectively, and the AUC and peak blood concentration of 14-hydroxyclarithromycin (active metabolite of clarithromycin) increased by 42% and 46%, respectively, compared to the values when administered alone. This increase in rabeprazole and 14-hydroxyclarithromycin exposure does not appear to be clinically significant.
8) In adverse reaction case reports, population pharmacokinetic studies, and retrospective studies, it has been reported that when methotrexate (mainly used in high doses, see precautions for the use of methotrexate) and proton pump inhibitors are used together, the serum concentration of methotrexate and/or its metabolite, hydroxymethotrexate, increases and is maintained, leading to methotrexate toxicity. However, formal drug interaction studies have not been conducted on high-dose methotrexate and proton pump inhibitors (see general precautions).
9) Antibiotic combination therapy for the eradication of Helicobacter pylori: When clarithromycin and/or erythromycin are administered together with pimozide, cardiac arrhythmias (including QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) occur, and this is due to the hepatic metabolism of these drugs being disturbed by clarithromycin and erythromycin, according to foreign post-marketing studies. and fatal cases have also been reported.
10) When this drug and rilpivirine are coadministered, the plasma concentration of rilpivirine may decrease (increased gastric pH), so coadministration should not be performed. This may reduce the therapeutic effect of rilpivirine.
6. Administration to pregnant and lactating women
1) There is no data on the safety of this drug in human pregnancy. This drug is contraindicated during pregnancy (in animal experiments, when administered orally during the organ formation period of pregnant rats (400 mg/kg/day), delayed ossification of the fetus, a decrease in the number of implantations at parturition, the number of survivors and the delivery rate, a decrease in the amount of birth weight gain, and a decrease in the number of trials and compartment transitions in an open-field test were observed. When administered intravenously before and after parturition (30 mg/kg/day), a continuous decrease in the birth weight was observed in pregnant rabbits. When administered intravenously (30 mg/kg/day) during the organogenesis period, decreased fetal weight and delayed ossification were observed.
2) It is not known whether this drug passes into human breast milk. No studies have been conducted in lactating women. Therefore, this drug should not be used during lactation (in animal experiments, it was reported to be secreted into breast milk, and a decrease in birth weight was observed when administered intravenously (30 mg/kg/day) before and after parturition in rats.)
7. Administration to the elderly: This drug is mainly metabolized in the liver, but the elderly often have reduced liver function and may experience adverse reactions. Therefore, if adverse reactions such as digestive symptoms (see Adverse Reactions section) appear, administer with caution, such as stopping the medication.
8. Administration to children: Safety in children has not been established (no experience with use).
9. Effect on clinical test values: Except for rare cases related to increased liver enzymes, there were no particularly abnormal results in laboratory test results.
10. Treatment in case of overdose: To date, there has been no experience of intentional overdose. Experience with overdose is limited. The highest confirmed dose does not exceed 60 mg twice daily or 160 mg once daily. The effects are generally mild and reversible without other medical treatment.
No special antidote is known. Rabeprazole sodium has a very high protein binding rate and is not easily dialyzed. In case of overdose, treatment should be conducted according to symptoms and overall supportive therapy should be provided.
11. Application precautions: Do not chew or crush this medicine. Swallow the tablet all at once.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
13. Others
1) There have been reports of visual impairment in foreign countries with other proton pump inhibitors (omeprazole).
2) For other proton pump inhibitor classes (omeprazole, lansoprazole), it has been reported that carotenoids were generated in the stomach in long-term oral administration toxicity tests in rats, and hyperplasia of enterochromaffin-like cells (ECL cells) was reported with this drug.
3) It has been reported that thyroid weight and blood thyroxine increased in animal experiments (oral administration to rats of 25 mg/kg or more), so be careful about thyroid function when using it.
4) In an in vitro reverse mutation test using bacteria, it was found to be a weak genetic mutation agent.
5) It was reported to be antigenic in animal tests.
6) In animal test data, the LD50 of rabeprazole sodium was > 1,000 mg/kg in mice and > 1,300 mg/kg in rats upon single oral administration. The lethal dose of rabeprazole sodium was > 2,000 mg/kg in dogs [approximately 2,500 to 5,000 times the recommended human dose (e.g., 20 mg/day)] when administered orally as a single dose, > 200 mg/kg in mice and > 150 mg/kg in rats when administered intravenously as a single dose. The peak plasma concentration after an initial oral dose of 100 mg/kg in mice, 300 mg/kg in rats, and 25 mg/kg in dogs was 8 to 37 times the peak plasma concentration in humans (Cmax = 427 ng/mL).
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
28 tablets (7 tablets/Alu-Alu×4)
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Rabeprazole sodium (JP, Byeolgyu) ----- 20mg
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow / pork, pork)
- Other additives: magnesium oxide, iron oxide, titanium oxide, sodium hydroxide, low-substituted hydroxypropyl cellulose, talc, polyethylene glycol 6000, hydroxypropyl cellulose, hypromellose phthalate, hypromellose 2910, D-mannitol.
2. Effectiveness
- Gastric ulcer, duodenal ulcer
- Erosive or ulcerative gastroesophageal reflux disease
- Relieve symptoms of gastroesophageal reflux disease
- Long-term maintenance treatment for gastroesophageal reflux disease
- Antibiotic combination therapy for patients with digestive ulcers infected with Helicobacter pylori
- Zollinger-Ellison syndrome
3. Dosage and dosage
- Gastric ulcer, duodenal ulcer: Usually, 10 mg of rabeprazole sodium is administered orally once a day to adults. Depending on symptoms, 20 mg can be administered orally once a day. Typically, it is administered for up to 8 weeks for gastric ulcers and up to 6 weeks for duodenal ulcers.
- Erosive or ulcerative gastroesophageal reflux disease: Administer 10 mg or 20 mg once a day for 4 to 8 weeks. If treatment is not achieved after 8 weeks of proton pump inhibitor (PPI) administration, 10 mg or 20 mg can be administered orally twice a day for an additional 8 weeks. However, administration of 20 mg twice daily is limited to patients with confirmed severe mucosal damage.
- Relief of symptoms of gastroesophageal reflux disease: Administer 10 mg once a day. If symptoms are not controlled even after 4 weeks of treatment, additional treatment is required. After symptoms disappear, subsequent symptoms can be controlled using on-demand therapy, administering 10 mg once a day when necessary.
- Long-term maintenance treatment for gastroesophageal reflux disease: 10 mg or 20 mg orally per day depending on the patient.
- Helicobacter pylori eradication: Patients with Helicobacter pylori infection should be treated with eradication therapy. It is recommended to administer 20 mg of this drug, 500 mg of clarithromycin, and 1 g of amoxicillin twice a day for 7 days.
- Zollinger-Ellison syndrome: The recommended initial dose for adults is 60 mg once a day. The dosage can be adjusted up to 120 mg per day depending on the needs of each patient. Up to a 100 mg dose can be administered once a day, and a 120 mg dose is administered in divided doses of 60 mg twice a day. Patients with Zollinger-Ellison syndrome have had experience taking this drug for up to one year.
- Patients with liver impairment: Adverse reactions of hepatic encephalopathy have been reported in patients with liver cirrhosis. Therefore, it must be administered with caution.
- Children: Safety in children has not been established.
- Elderly: Administer with caution as liver function is often reduced.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug, its components, or benzimidazoles
2) Patients with hypersensitivity to penicillin antibiotics (when combined with amoxicillin to eradicate Helicobacter pylori)
3) Patients with hypersensitivity to macrolide antibiotics (limited to combined use with clarithromycin to eradicate Helicobacter pylori)
4) Patients receiving terfenadine, cisapride, pimozide, and astemizole (limited to combined use with clarithromycin to eradicate Helicobacter pylori) (see interaction section)
5) Patients receiving atazanavir
6) Pregnant and lactating women
7) Patients taking rilpivirine (see interaction section)
2. Administer with caution to the following patients:
1) Patients with liver impairment
2) Elderly people (refer to the section on administration to elderly people)
3) Patients with a history of drug hypersensitivity reaction
3. Adverse reactions
1) Hypersensitivity reaction: Occasionally rash, hives, and itching may occur. If these symptoms appear, discontinue administration.
2) Blood system: Decreased red blood cells, decreased leukocytes, increased leukocytes, increased eosinophilia, increased neutrophils, decreased lymphocytes, anemia, ecchymosis, lymphadenopathy, hypochromic anemia, decreased pancytemia, agranulocytosis, decreased thrombocytopenia, hemolytic anemia, etc. may occur, so it is advisable to perform regular hematological tests during administration. Additionally, if abnormalities appear, take appropriate measures, such as discontinuing administration.
3) Liver: Occasionally, elevations of ALT, AST, ALP, γ-GTP, LDH, and total bilirubin may occur, so it is advisable to conduct blood biochemical tests regularly during administration. Fulminant hepatitis, liver dysfunction, and jaundice may occur. If abnormalities appear, take appropriate measures, such as discontinuing administration.
4) Cardiovascular system: Hypertension, myocardial infarction, electrocardiogram abnormalities, migraine, syncope, angina pectoris, bundle branch block, palpitations, sinus bradycardia, tachycardia, rarely bradycardia, pulmonary embolism, supraventricular tachycardia, thrombophlebitis, vasodilatation, QTC prolongation, and ventricular tachycardia may occur.
5) Digestive system: Diarrhea, occasional constipation, abdominal pain, abdominal distension, indigestion, belching, nausea, rectal bleeding, bloody stool, anorexia, cholelithiasis, oral ulcer, dysphagia, gingivitis, cholanitis, hyperappetite, abnormal stool, colitis, esophagitis, glossitis, pancreatitis, proctitis, rarely dry mouth, vomiting, lower abdominal pain, gastric body, gastritis, stomatitis, dysgeusia, hemorrhagic diarrhea, Cholangitis, duodenitis, gastrointestinal bleeding, hepatic encephalopathy, hepatitis, liver cancer, liver fat accumulation, salivary gland enlargement, and thirst may occur.
6) Mental nervous system: Headache, insomnia, anxiety, dizziness, convulsions, abnormal dreams, decreased libido, neuropathy, paresthesia, tremors, sometimes asthenia, nervousness, drowsiness, and in rare cases, vertigo and depression may occur. In rare cases, agitation, amnesia, confusion, extrapyramidal syndrome, and excessive circulating blood flow may occur. In addition, in one case of a cirrhotic patient, there were reports of upper and lower extremity weakness, dullness of perception, decreased grip strength, speech confusion, and staggering, and in one case of a cirrhotic patient with a previous history of hepatic coma in a foreign country, there were reports of confusion, disorientation, and lethargy.
7) Respiratory system: Cough, pharyngitis, rhinitis, difficulty breathing, asthma, nosebleeds, laryngitis, hiccups, hyperventilation, and sometimes bronchitis and sinusitis may occur. In rare cases, apnea and respiratory depression may occur. Since interstitial pneumonia may occur, if fever, cough, difficulty breathing, abnormal lung sounds, etc. are confirmed, administration of this drug should be discontinued, a chest X-ray should be promptly performed, and appropriate measures should be taken.
8) Musculoskeletal system: Muscle pain, back pain, arthritis, leg cramps, bone pain, arthrosis, bursitis, hypertonia, neuralgia, and in rare cases, single contraction may occur.
9) Skin and appendages: Rash, itching, sweating, urticaria, alopecia, rarely dry skin, shingles, psoriasis, skin color change, toxic epidermal necrolysis (Riel syndrome), mucocutaneous ocular syndrome (Stevens-Johnson syndrome), and erythema multiforme may occur.
10) Special senses: Cataracts, amblyopia, glaucoma, dry eyes, abnormal vision, tinnitus, otitis media, rarely corneal opacity, blurred vision, double vision, hearing loss, eye pain, retinal degeneration, and strabismus may occur.
11) Urinary system: Proteinuria, cystitis, frequent urination, dysmenorrhea, dysuria, renal stones, uterine bleeding, polyuria, rarely breast enlargement, hematuria, erectile dysfunction, vaginal discharge, menorrhagia, orchitis, urinary incontinence, interstitial renal tubulitis (possibility of progressing to renal failure) may occur.
12) Others: Occasionally, edema, elevation of total cholesterol, neutral fat, BUN, thyroid stimulating hormone in the blood, chest pain, chills, fever, urinary tract infection, erythema, and in rare cases, malaise, weight gain, visual abnormalities, loss of appetite, neck stiffness, photosensitivity reaction, hangover effect, weight loss, and gout may occur. There are reports that other proton pump inhibitor drugs (omeprazole, lansoprazole) rarely cause anaphylactic reactions and shock, so if abnormalities appear, stop administration and take appropriate measures.
13) Adverse reactions reported in foreign countries after marketing
Elevated liver enzyme levels have been reported, and in rare cases, hepatitis and jaundice have been reported. Hepatic encephalopathy has been rarely reported in patients with cirrhosis. Sudden death, coma, hyperammonemia, rhabdomyolysis, disorientation, delirium, anaphylaxis, and angioedema have been reported. Additionally, in rare cases, hypomagnesemia, thrombocytopenia, neutropenia, leukopenia, agranulocytosis, hemolytic anemia, pancytopenia, bullous or urticarial skin rash, systemic allergic reactions (hypotension, dyspnea, facial edema, etc.), muscle pain, and arthralgia have been reported. Very rarely, interstitial nephritis, gynecomastia, interstitial pneumonia, elevated thyroid-stimulating hormone, erythema multiforme, toxic epidermal necrolysis (Riel syndrome), and mucocutaneous ocular syndrome (Stevens-Johnson syndrome) have been reported. Increases in INR and prothrombin time have been reported when used in combination with warfarin. Bone fractures have been reported. No other significant abnormal results related to rabeprazole treatment were reported in laboratory tests. Clostridium difficile diarrhea may occur (frequency unknown).
The following are adverse reactions reported through post-marketing surveillance of proton pump inhibitors. Because these adverse reactions are voluntarily reported from an unspecified population, it is not always possible to reliably predict their incidence or establish a causal relationship with drug administration.
- Immune system: Systemic lupus erythematosus
- Skin and subcutaneous tissue system: Cutaneous lupus erythematosus
14) Domestic post-marketing survey results
As a result of a use result survey conducted on 53,109 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 0.47% (250 cases/53,109 cases) regardless of causal relationship.
(1) Digestive system: nausea, constipation, abdominal pain, diarrhea, indigestion, abdominal distension, burping, dry mouth, bad breath, glossitis, dry mouth, vomiting, abnormal taste, gastritis, abnormal liver function, increased ALT, increased AST
(2) Systemic and metabolic abnormalities: chest tightness, allergic reaction, fever, edema, hypertriglyceridemia, hypercholesterolemia, weight loss
(3) Nervous system: headache, dizziness, confusion, asthenia, numbness in hands and feet, anxiety, insomnia, drowsiness
(4) Skin and appendages: hives, rash, itching, facial swelling, flushing
(5) Musculoskeletal system: joint pain, muscle pain
(6) Respiratory system: cough, difficulty breathing
(7) Others: palpitations, increased intraocular pressure, visual abnormalities, urinary tract infection
4. General precautions
1) This drug may alleviate the symptoms of malignant tumor or delay the diagnosis, so if there are warning symptoms of suspected malignant tumor (unintentional significant weight loss, recurrent vomiting, difficulty swallowing, hematemesis, melena, etc.) and gastric ulcer is present or suspected, the drug must be administered after confirming that it is not malignant.
2) During treatment, the progress should be observed sufficiently and this drug should be administered at the minimum dose and appropriate treatment period depending on the symptoms. When undergoing long-term treatment with this drug (especially more than 1 year), patients should be examined regularly.
3) No dosage adjustment is necessary for patients with renal impairment. While taking this drug, it is advisable to pay attention to blood status and liver function and perform regular hematological and blood biochemical tests. Additionally, if abnormalities are recognized, appropriate measures, such as discontinuation of administration, are taken.
4) Because there is insufficient long-term use experience for gastric ulcers, duodenal ulcers, and anastomotic ulcers, it is not recommended to use it for maintenance therapy.
5) In an observational study, it was reported that proton pump inhibitor treatment may be associated with an increased risk of fractures associated with osteoporosis of the hip, wrist, and spine. The risk of fracture was increased in patients receiving higher doses than the recommended dose and in patients using the drug for long-term use of more than 1 year.
6) Hypomagnesemia was rarely reported in patients treated with proton pump inhibitors for more than 3 months, and was most common in patients treated for more than 1 year. For most patients, treatment of hypomagnesemia requires magnesium supplementation and discontinuation of proton pump inhibitors. Patients requiring long-term treatment or taking concomitant medications such as digoxin or drugs that cause hypomagnesemia (e.g. diuretics) require periodic monitoring of magnesium levels, including at the start of treatment. Serious adverse reactions include rigidity, arrhythmias, and seizures.
7) When stomach acidity decreases due to proton pump inhibitors, the number of bacteria normally present in the gastrointestinal tract increases. Treatment with this medicine may slightly increase the risk of infections of the gastrointestinal tract caused by bacteria such as Salmonella, Campylobacter, and Clostridium difficile. This is associated with an increased risk of Clostridium difficile diarrhea, and several observational studies have reported that this risk is particularly increased in hospitalized patients. This diagnosis should be considered when diarrhea symptoms do not improve. Clostridium difficile diarrhea has been reported during use of almost all antibacterial agents.
8) Based on the pharmacological properties and adverse reactions that occurred, this drug is not expected to affect driving ability or the ability to operate machinery. However, as drowsiness can reduce your agility, avoid driving or operating complex machinery.
9) Methotrexate: There have been literature reports that when proton pump inhibitors and methotrexate are used together (mainly when using high doses, see precautions for the use of methotrexate), the serum concentration of methotrexate and/or its metabolites increases and persists, leading to methotrexate toxicity. When high doses of methotrexate are used, temporary discontinuation of the proton pump inhibitor may be considered (see Interaction section).
10) As a combination therapy with antibiotics to eradicate Helicobacter pylori, you should refer to the instructions for use of the antibacterial agent administered together with this drug.
11) Long-term administration of this drug may cause vitamin B12 (cyanocobalamin) malabsorption due to hypochlorhydria or anacidosis.
12) Skin and systemic lupus erythematosus: Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking proton pump inhibitors. These cases occurred newly or as a result of worsening of existing autoimmune diseases. Most cases of lupus erythematosus caused by proton pump inhibitors were cutaneous lupus erythematosus.
The most common form of cutaneous lupus erythematosus reported in patients taking proton pump inhibitors is subacute cutaneous lupus erythematosus, which occurs within weeks to years of continuous drug treatment in patients ranging from infants to the elderly. In general, histological results showed no organ invasion.
Systemic lupus erythematosus has been reported less commonly than cutaneous lupus erythematosus in patients taking proton pump inhibitors. Proton pump inhibitor-related systemic lupus erythematosus usually shows milder symptoms than non-drug-induced systemic lupus erythematosus. Systemic lupus erythematosus mainly occurs within a few days to several years after initial drug treatment in young adults to the elderly. The majority of patients presented with a rash, but arthralgia and cytopenias were also reported.
Do not take proton pump inhibitors for longer than medically indicated. If a patient taking this drug develops symptoms or signs consistent with cutaneous lupus erythematosus or systemic lupus erythematosus, stop taking the drug and refer the patient to an appropriate specialist for evaluation. Most patients improved simply by discontinuing proton pump inhibitors within 4 to 12 weeks. Serological tests (e.g., antinuclear antibody (ANA)) may be positive, and high serological test results may take longer to resolve than clinical symptoms.
13) The decrease in gastric acidity caused by the administration of this drug increases the concentration of serum chromogranin A (CgA). Therefore, people taking this drug may experience false positive results in neuroendocrine tumor diagnostic tests. Administration of this drug should be temporarily discontinued at least 14 days before the CgA test. If the test value exceeds the upper reference limit, retesting should be considered. When tests are performed repeatedly (e.g., monitoring), concentration measurements should be performed in the same laboratory because reference ranges differ between laboratories.
14) Acute interstitial renal tubulitis: Acute interstitial renal tubulitis has been observed in patients receiving proton pump inhibitors and can occur at any time during proton pump inhibitor treatment. Patients may exhibit a variety of signs and symptoms, ranging from hypersensitivity reactions to non-specific symptoms of renal dysfunction (e.g., malaise, nausea, loss of appetite). In reported case series, some patients were diagnosed by biopsy and had no extrarenal symptoms (e.g. fever, rash, arthralgia).
Acute interstitial renal tubulitis may progress to renal failure.
Patients suspected of having acute interstitial renal tubulitis should discontinue treatment with this drug and take appropriate measures.
5. Interaction
1) Like other proton pump inhibitor drugs, this drug is metabolized through the CYP-450 system, a hepatic metabolic system. In tests conducted on healthy adults, this drug did not show clinically significant interactions with amoxicillin or drugs metabolized by the CYP-450 system such as warfarin, phenytoin, theophylline, and diazepam. (Omeprazole, another PPI drug, has been reported to delay the metabolism and excretion of phenytoin.)
There have been reports of increased INR and prothrombin time in patients receiving warfarin in combination with proton pump inhibitors, including this drug. Increased INR and prothrombin time can cause abnormal bleeding and even death.
2) In in vitro tests with human liver microsomes, this drug was metabolized by CYP-450 (CYP2C19 and CYP3A4) enzymes. In these tests, blood concentrations of rabeprazole in humans did not inhibit or induce CYP3A4. In an in vitro test with human liver microsomes, this drug inhibited the metabolism of cyclosporine, and the IC50 was 62 μM, which is more than 50 times the highest blood concentration measured in healthy volunteers after taking 20 mg for 14 days. This degree of inhibition is similar to that of omeprazole at the same concentration.
3) Atazanavir - When atazanavir 300 mg/ritonavir 100 mg and omeprazole (40 mg once daily) or atazanavir 400 mg and lansoprazole (60 mg once daily) were coadministered to healthy volunteers, atazanavir exposure was substantially reduced. Atazanavir absorption is pH dependent. Concomitant administration with this drug has not been studied, but similar results are expected as with other proton pump inhibitors. Therefore, proton pump inhibitors, including this drug, should not be administered simultaneously with atazanavir.
4) This drug inhibits gastric acid secretion significantly and continuously for a long period of time. There may be interactions with drugs whose absorption varies depending on the concentration of stomach acid. When administered in combination with this drug, the blood concentration of ketoconazole decreased by approximately 30% and the trough blood concentration of digoxin increased by 22% in normal subjects. Additionally, when this drug is administered together with itraconazole and gefitinib, there is a risk that the blood concentration of these drugs may decrease. Therefore, if dose adjustment is necessary due to co-administration of these drugs and this drug, it should be determined through monitoring for each patient.
5) In clinical trials conducted to check the interaction with antacids when using this drug together with antacids, no interaction was observed with liquid antacids. There have been reports that the average area under the blood concentration curve decreased by 8% and 6%, respectively, when this drug was administered simultaneously with aluminum hydroxide gel and an antacid containing magnesium hydroxide and when taken 1 hour after the administration of the antacid.
6) In a Japanese clinical trial in which a low-fat diet was consumed, there were no clinically relevant interactions with food. When this drug is administered with a high-fat meal, absorption of this drug may be delayed for up to 4 hours or more, but the extent of absorption (AUC) and peak blood concentration remain unchanged.
7) Combination treatment with antibiotics: 20 mg of this drug, 1,000 mg of amoxicillin, and 500 mg of clarithromycin were administered alone or in combination to 16 healthy volunteers, and a cross-over test was conducted. The AUC and peak blood concentrations of clarithromycin and amoxicillin were similar to those of monotherapy. The AUC and peak blood concentration of rabeprazole increased by 11% and 34%, respectively, and the AUC and peak blood concentration of 14-hydroxyclarithromycin (active metabolite of clarithromycin) increased by 42% and 46%, respectively, compared to the values when administered alone. This increase in rabeprazole and 14-hydroxyclarithromycin exposure does not appear to be clinically significant.
8) In adverse reaction case reports, population pharmacokinetic studies, and retrospective studies, it has been reported that when methotrexate (mainly used in high doses, see precautions for the use of methotrexate) and proton pump inhibitors are used together, the serum concentration of methotrexate and/or its metabolite, hydroxymethotrexate, increases and is maintained, leading to methotrexate toxicity. However, formal drug interaction studies have not been conducted on high-dose methotrexate and proton pump inhibitors (see general precautions).
9) Antibiotic combination therapy for the eradication of Helicobacter pylori: When clarithromycin and/or erythromycin are administered together with pimozide, cardiac arrhythmias (including QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) occur, and this is due to the hepatic metabolism of these drugs being disturbed by clarithromycin and erythromycin, according to foreign post-marketing studies. and fatal cases have also been reported.
10) When this drug and rilpivirine are coadministered, the plasma concentration of rilpivirine may decrease (increased gastric pH), so coadministration should not be performed. This may reduce the therapeutic effect of rilpivirine.
6. Administration to pregnant and lactating women
1) There is no data on the safety of this drug in human pregnancy. This drug is contraindicated during pregnancy (in animal experiments, when administered orally during the organ formation period of pregnant rats (400 mg/kg/day), delayed ossification of the fetus, a decrease in the number of implantations at parturition, the number of survivors and the delivery rate, a decrease in the amount of birth weight gain, and a decrease in the number of trials and compartment transitions in an open-field test were observed. When administered intravenously before and after parturition (30 mg/kg/day), a continuous decrease in the birth weight was observed in pregnant rabbits. When administered intravenously (30 mg/kg/day) during the organogenesis period, decreased fetal weight and delayed ossification were observed.
2) It is not known whether this drug passes into human breast milk. No studies have been conducted in lactating women. Therefore, this drug should not be used during lactation (in animal experiments, it was reported to be secreted into breast milk, and a decrease in birth weight was observed when administered intravenously (30 mg/kg/day) before and after parturition in rats.)
7. Administration to the elderly: This drug is mainly metabolized in the liver, but the elderly often have reduced liver function and may experience adverse reactions. Therefore, if adverse reactions such as digestive symptoms (see Adverse Reactions section) appear, administer with caution, such as stopping the medication.
8. Administration to children: Safety in children has not been established (no experience with use).
9. Effect on clinical test values: Except for rare cases related to increased liver enzymes, there were no particularly abnormal results in laboratory test results.
10. Treatment in case of overdose: To date, there has been no experience of intentional overdose. Experience with overdose is limited. The highest confirmed dose does not exceed 60 mg twice daily or 160 mg once daily. The effects are generally mild and reversible without other medical treatment.
No special antidote is known. Rabeprazole sodium has a very high protein binding rate and is not easily dialyzed. In case of overdose, treatment should be conducted according to symptoms and overall supportive therapy should be provided.
11. Application precautions: Do not chew or crush this medicine. Swallow the tablet all at once.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
13. Others
1) There have been reports of visual impairment in foreign countries with other proton pump inhibitors (omeprazole).
2) For other proton pump inhibitor classes (omeprazole, lansoprazole), it has been reported that carotenoids were generated in the stomach in long-term oral administration toxicity tests in rats, and hyperplasia of enterochromaffin-like cells (ECL cells) was reported with this drug.
3) It has been reported that thyroid weight and blood thyroxine increased in animal experiments (oral administration to rats of 25 mg/kg or more), so be careful about thyroid function when using it.
4) In an in vitro reverse mutation test using bacteria, it was found to be a weak genetic mutation agent.
5) It was reported to be antigenic in animal tests.
6) In animal test data, the LD50 of rabeprazole sodium was > 1,000 mg/kg in mice and > 1,300 mg/kg in rats upon single oral administration. The lethal dose of rabeprazole sodium was > 2,000 mg/kg in dogs [approximately 2,500 to 5,000 times the recommended human dose (e.g., 20 mg/day)] when administered orally as a single dose, > 200 mg/kg in mice and > 150 mg/kg in rats when administered intravenously as a single dose. The peak plasma concentration after an initial oral dose of 100 mg/kg in mice, 300 mg/kg in rats, and 25 mg/kg in dogs was 8 to 37 times the peak plasma concentration in humans (Cmax = 427 ng/mL).
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
28 tablets (7 tablets/Alu-Alu×4)
7. Period of use
36 months from date of manufacture
Product Updates
Total 5items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 5 | Bepzole Tab. 20mg | Precautions for use | 2023.06.03 | PDF0004_201403760_Precautions for use (Befzol tablets 20mg).pdf |
| 4 | Befzol Tablet 20mg | Befzol Tablet 20mg (Precautions for use) | 2018.07.04 | PDFBefzol Tablet 20mg .pdf |
| 3 | Befzol Tablet 20mg | Befzol Tablet 20mg (Precautions for use) | 2017.04.20 | HWP58_Bepzol Tablet 20mg.hwp |
| 2 | Befzol Tablet 20mg | Befzol Tablet 20mg (Precautions for use) | 2016.07.25 | HWP62_Bepzol tablets 10 milligrams.hwp |
| 1 | Befzol Tablet 20mg | Befzol Tablet 20mg (Precautions for use) | 2015.07.03 | HWPPermission_change order_rabeprazole single agent (oral).hwp |